Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial of Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-del (5q) MDS Patients

NCT01133275 is registered in ClinicalTrials.gov with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor.

NCT NCT01133275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01133275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial of Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-del (5q) MDS Patients
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Phase
Phase 2
Overall status
Completed
Start date
April 28, 2010
Completion date
November 21, 2019
Enrollment
28 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

mds, myelodysplastic syndrome